DBV Technologies fell 28.8% in a year. Moderna rose 10.5-fold.

Same industry

DBVT against four biotech peers, a year at 100

DBVT is down 28.8% in a year. Moderna is up 10.5 times, Biogen is up 63.6%, Amgen 49.4% and Gilead Sciences 46.8%. All four did more. Weekly closes, Nov 7, 2025 = 100, on a log scale so a 10.5-fold rise and a 28.8% fall both read honestly.

Share this chart

DBVT −28.8%. Moderna ×10.5, Biogen +63.6%, Amgen +49.4%, Gilead Sciences +46.8%. Weekly closes, Nov 7, 2025 = 100, log scale.

Share this chart

End-of-day closes (Databento EOD), the last close of each week. The four peers are the largest US-listed companies by market value in DBVT’s SEC industry (Biological Products, (No Diagnostic Substances)) with a year of closes. It shows what the closes did; a move here is not a cause, a forecast or a call.

DBVT: stories, the record and filings →